Developer docs
API playgroundTry for free, no card

Search company profiles

Celltheon

Full company profile

uuid00022mc

Namestring
Celltheon
Legal namestring
Celltheon Corporation
Websiteurl
celltheon.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Celltheon Corporation is a privately held cell line development and contract research company founded in 2012 and headquartered in Union City, California. The company builds and applies a proprietary CHO-K1 based protein expression platform — branded as the CELLTHEON SMART™ Expression Platform — to help pharmaceutical and biotechnology clients produce complex biologics, difficult-to-express proteins (DEPs), bispecifics, heterodimeric IgGs, biosimilars, and other challenging antibody formats. The platform integrates multiple internally developed and trademarked technologies: SUPERCELL™ engineered host cells (with custom KO/KI capabilities), pCT™ vectors incorporating CT STABILIZER™ and SIREN Promoter™ genetic elements, GOLDILOCKS TRANSPOSASE™ for stable cell line generation, CHROMASelect™ clone screening (evaluating over 100 million clones for titer, glycoforms, aggregation, and clipping), and SMART BIOPROCESSING™ for upstream and downstream optimization.

The company's commercial offering spans end-to-end biologics development services — developability optimization, transient production, stable cell line development (with claimed >8 g/L titers and 4.5 months to Research Cell Bank), upstream and downstream process development, biochemical and biological analytics, GLP-compliant tox material production up to 100 g per batch, and tech transfer to CDMOs — and, as of October 2024, a catalog product, the OmniCHO™ Transient Kit, the company's first off-the-shelf CHO-K1 transient expression system.

Revenue derives primarily from custom, quote-based contract services sold through direct enterprise field sales to pharma and biotech clients (100+ global clients served cumulatively, with 1000+ therapeutic proteins developed since inception). The October 2024 OmniCHO launch introduces a transactional kit revenue stream, with pricing not publicly disclosed. Distribution is direct (via email orders and HubSpot contact forms), with channel partnerships through CDMOs for downstream GMP manufacturing and Sepragen Corporation for chromatography equipment. The team of 11–50 is led by founder/CEO Amita Goel (25+ years pharma experience at Elan Pharmaceuticals and Arresto Biosciences/Gilead), supported by a CTO and a scientific advisory board drawn from Genentech, Gilead, Pfizer, Amgen, Eli Lilly, and other major biopharma organizations.

Short descriptiontext

Celltheon is a contract research organization specializing in cell line development and protein expression for complex biologics and difficult-to-express proteins, serving 100+ global pharmaceutical and biotechnology clients with its proprietary CHO-K1 based CELLTHEON SMART™ platform and OmniCHO™ transient kit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUnion City, United States
HQ citystring
Union City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell line development, biologics contract services, protein expression platforms, CHO cell engineering, bioprocess development
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Contract Development & Manufacturing Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Custom Contract Services
TypeProfessional Services
Description

End-to-end biologics development services including cell line development, process development, analytical characterization, GLP bioproduction, and tech transfer. Services are custom-tailored to each client's drug program with pricing based on project scope and complexity.

celltheon.com
2OmniCHO™ Transient Kit Sales
TypeOne Time License
Description

Sale of OmniCHO Transient Expression Kit containing vectors, cells, media, and transfection agent. Kit is sold as a unit product for customers conducting transient expression workflows.

celltheon.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1OmniCHO Transient Kit - Single Unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Kit contents include vectors, SUPERCELLs, media, and ACF-T transfection agent. Pricing not publicly disclosed - contact orders@celltheon.com for quote.

celltheon.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1CELLTHEON SMART™ Expression Platform
Description

A universal platform for all protein formats including IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, and single chain homotrimer.

celltheon.com
+6 more records
Core offering1 text field

Celltheon provides custom contract development and manufacturing services for complex biologics, including cell line development, upstream/downstream process development, analytical characterization, GLP bioproduction, and tech transfer. The company leverages a proprietary CHO-K1 based protein expression platform (CELLTHEON SMART Expression Platform) powered by engineered SUPERCELLs, pCT vectors, GOLDILOCKS transposase, CHROMASelect screening, and SMART BIOPROCESSING. Celltheon also sells the OmniCHO Transient Expression Kit as a standalone commercial product for customers performing in-house transient expression.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • Up to 4.5 g/L transient titers (OmniCHO)
+9 more records
Product overview1 text field

Celltheon offers a portfolio of commercial products and an integrated service platform for complex biologics development and manufacturing. OmniCHO™ is a commercial transient expression kit (the first high-performance CHO-K1 transient kit), while the CELLTHEON SMART™ Expression Platform is a universal preclinical development platform supporting all protein formats. The platform is powered by proprietary technologies including SUPERCELL™ engineered CHO cells, pCT™ Vectors (with CT STABILIZER™ and SIREN Promoter™), GOLDILOCKS TRANSPOSASE™, CHROMASelect™ screening (>100M clones), and SMART BIOPROCESSING™. The company provides end-to-end services spanning developability optimization, transient production, cell line development (5-10g/L titers), upstream/downstream process development, analytical characterization, GLP bioproduction (up to 100g/batch), and tech transfer. Services support multiple protein formats including IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, and single chain homotrimer.

Product and service11 records
1OmniCHO Transient Kit
CategoryTransient Expression Reagents
Description

First high-performance CHO-K1 based transient expression kit (vectors, cells, media, transfection agent) for customers performing in-house transient expression workflows, achieving transient titers up to 4.5 g/L with up to 14x improvement over market-leading transient kits for mAbs and >20x improvement for difficult-to-express proteins.

2CELLTHEON SMART Expression Platform (Custom Contract Services)
CategoryContract Development Services
Description

Universal preclinical development platform supporting all protein formats (IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, single chain homotrimer) with integrated cell line development, process development, analytical characterization, GLP bioproduction, and tech transfer services for biopharma clients developing complex biologics.

3Cell Line Development Service
CategoryContract Development Services
Description

High-titer stable cell line development achieving >8 g/L clones and >3 g/L pools, stable clones stable for >60 generations, with delivery of 4.5 months to RCB or 6 months with full upstream/downstream process development.

4Upstream Process Development Service
CategoryContract Development Services
Description

Robust upstream process development using stirred-tank bioreactors with 100% reproducibility in ≥200L STR bioreactors, including CQA optimization for charge variants, N-glycan, truncation, and aggregation.

5Downstream Process Development Service
CategoryContract Development Services
Description

Scalable 3-4 column chromatography process development optimized for high yield and purity, including viral inactivation, filtration, clarification, and formulation via TFF.

6Developability Optimization Service
CategoryContract Development Services
Description

Assessment and optimization of protein developability properties to improve downstream processing success.

7Transient Production Service
CategoryContract Manufacturing Services
Description

Rapid production, purification, and characterization of hundreds of protein variants with average mAb titers of 2.0 gm/L in 4-5 day culture using CHO and HEK293 cells.

8Biochemical Analytics Service
CategoryAnalytical Services
Description

High-resolution analytical method development including SE-HPLC, LAL endotoxin, titer, ELISA, RP-HPLC, HIC-HPLC, CEX-HPLC, N-Glycan HILIC-HPLC, and kinetics assays.

9Biological Activity Assay Development Service
CategoryAnalytical Services
Description

Cell-based assay development including FACS, cytokine release, cell killing assays, ADCC, CDC, transwell, and custom assays for biological activity characterization.

10Tox Material Production Service
CategoryContract Manufacturing Services
Description

GLP production of high-quality tox study materials with stirred-tank bioreactors up to 100 grams per production batch and low endotoxin (<0.05 EU/mg).

11Tech Transfer Service
CategoryContract Manufacturing Services
Description

Seamless technology transfer of manufacturing processes to CDMOs with GMP-ready BOM, continuous SME support, and 100% successful process reproducibility.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Sepragen Corporation
Strategic tierCoreTypeTechnology or Integration
Description

Sepragen Corporation provides bio-processing equipment and consumables for protein production and purification. Their technology, covered by 16 patents, is used globally by leading pharma companies. Sepragen's equipment enables Celltheon to expand its biomanufacturing capabilities. Founder/CEO Vinit Saxena serves as Celltheon advisor on chromatography.

celltheon.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Amita Goel is an ABCAB Board Member at Keck Graduate Institute. Dr. Parviz Shamlou previously served as Director of the Amgen Bioprocessing Center at Keck Graduate Institute. Collaborative relationship through board involvement and advisory roles.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Celltheon supports tech transfer to CDMOs for GMP clinical production. Claims 100% process reproducibility in ≥200L STR bioreactors at partner manufacturing sites. Continuous SME support during entire project lifecycle.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GenScript ProBio is the CDMO arm of GenScript, offering end-to-end biologics development from cell line construction through GMP manufacturing for mAbs, bsAbs, and recombinant proteins. It is a broader incumbent with similar services but at larger scale and broader geographic reach.

TypeBroad incumbent
Description

AGC Biologics is a global CDMO offering mammalian cell line development, process development, and GMP manufacturing for biologics. It competes with Celltheon on cell line and process development but at substantially larger scale across multiple sites.

TypeEmerging player
Description

AbCellera is a clinical-stage biotech and antibody discovery platform with proprietary technology for identifying and engineering antibodies, including cell line and expression capabilities for difficult-to-express biologics. It is comparable as a technology-driven biologics platform with selective CDMO-like service offerings.

TypeBroad incumbent
Description

Catalent is a major global CDMO providing cell line development, bioprocess development, and GMP manufacturing for biologics. It is comparable as a broad incumbent serving the same enterprise biopharma customers with overlapping upstream services.

TypeDirect peer
Description

ATUM (formerly DNA2.0) is a direct peer offering proprietary cell line development and protein expression tools, including its Leap-In Transposase system and CHO/HEK platforms. It competes head-to-head with Celltheon on CHO-based expression technology and synthetic biology services for biologics developers.

TypeBroad incumbent
Description

Samsung Biologics is a top-tier global CDMO offering cell line development, process development, and large-scale GMP biologics manufacturing services. It competes with Celltheon as a much larger incumbent serving the same biopharma client base.

TypeDirect peer
Description

LakePharma, now part of Curia, provides contract biologics development and manufacturing services including cell line development, process development, and analytical characterization for mAbs and recombinant proteins. It overlaps directly with Celltheon's end-to-end biologics services offering.

8KBI Biologics
TypeDirect peer
Description

KBI Biologics is a contract development and manufacturing organization specializing in mammalian cell line development, process development, and cGMP biomanufacturing for mAbs and recombinant proteins. It is a close comparable as a mid-sized biologics CDMO competing for similar biopharma customers.

TypeBroad incumbent
Description

WuXi Biologics is a leading global biologics CDMO with end-to-end capabilities from cell line development through commercial manufacturing. It is a broad incumbent competing for the same biologics development projects as Celltheon across global biopharma.

TypeBroad incumbent
Description

Lonza is one of the world's largest biologics CDMOs, offering comprehensive cell line construction (e.g., GS Xceed), process development, and large-scale GMP manufacturing. It overlaps with Celltheon on cell line development and process development for mAbs and recombinant proteins.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celltheon

Biologics Contract Development & Manufacturing Servicescelltheon.com

Celltheon is a contract research organization specializing in cell line development and protein expression for complex biologics and difficult-to-express proteins, serving 100+ global pharmaceutical and biotechnology clients with its proprietary CHO-K1 based CELLTHEON SMART™ platform and OmniCHO™ transient kit.

What Celltheon does

Celltheon Corporation is a privately held cell line development and contract research company founded in 2012 and headquartered in Union City, California. The company builds and applies a proprietary CHO-K1 based protein expression platform — branded as the CELLTHEON SMART™ Expression Platform — to help pharmaceutical and biotechnology clients produce complex biologics, difficult-to-express proteins (DEPs), bispecifics, heterodimeric IgGs, biosimilars, and other challenging antibody formats. The platform integrates multiple internally developed and trademarked technologies: SUPERCELL™ engineered host cells (with custom KO/KI capabilities), pCT™ vectors incorporating CT STABILIZER™ and SIREN Promoter™ genetic elements, GOLDILOCKS TRANSPOSASE™ for stable cell line generation, CHROMASelect™ clone screening (evaluating over 100 million clones for titer, glycoforms, aggregation, and clipping), and SMART BIOPROCESSING™ for upstream and downstream optimization.

The company's commercial offering spans end-to-end biologics development services — developability optimization, transient production, stable cell line development (with claimed >8 g/L titers and 4.5 months to Research Cell Bank), upstream and downstream process development, biochemical and biological analytics, GLP-compliant tox material production up to 100 g per batch, and tech transfer to CDMOs — and, as of October 2024, a catalog product, the OmniCHO™ Transient Kit, the company's first off-the-shelf CHO-K1 transient expression system.

Revenue derives primarily from custom, quote-based contract services sold through direct enterprise field sales to pharma and biotech clients (100+ global clients served cumulatively, with 1000+ therapeutic proteins developed since inception). The October 2024 OmniCHO launch introduces a transactional kit revenue stream, with pricing not publicly disclosed. Distribution is direct (via email orders and HubSpot contact forms), with channel partnerships through CDMOs for downstream GMP manufacturing and Sepragen Corporation for chromatography equipment. The team of 11–50 is led by founder/CEO Amita Goel (25+ years pharma experience at Elan Pharmaceuticals and Arresto Biosciences/Gilead), supported by a CTO and a scientific advisory board drawn from Genentech, Gilead, Pfizer, Amgen, Eli Lilly, and other major biopharma organizations.

Celltheon firmographics

Firmographics
Name
Celltheon
Legal name
Celltheon Corporation
Website
https://celltheon.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Celltheon is a contract research organization specializing in cell line development and protein expression for complex biologics and difficult-to-express proteins, serving 100+ global pharmaceutical and biotechnology clients with its proprietary CHO-K1 based CELLTHEON SMART™ platform and OmniCHO™ transient kit.
Ownership category
akta.pro rank

Celltheon industry classification

Industry
Product category
Biologics Contract Development & Manufacturing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell line development
  • Biologics contract services
  • Protein expression platforms
  • CHO cell engineering
  • Bioprocess development

Where Celltheon is headquartered

Location

Headquarters

HQ city
Union City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Celltheon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Custom Contract Services: End-to-end biologics development services including cell line development, process development, analytical characterization, GLP bioproduction, and tech transfer. Services are custom-tailored to each client's drug program with pricing based on project scope and complexity.
  2. OmniCHO™ Transient Kit Sales: Sale of OmniCHO Transient Expression Kit containing vectors, cells, media, and transfection agent. Kit is sold as a unit product for customers conducting transient expression workflows.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOmniCHO Transient Kit - Single Unit

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Celltheon product offering

Product offering

Core offering

Celltheon provides custom contract development and manufacturing services for complex biologics, including cell line development, upstream/downstream process development, analytical characterization, GLP bioproduction, and tech transfer. The company leverages a proprietary CHO-K1 based protein expression platform (CELLTHEON SMART Expression Platform) powered by engineered SUPERCELLs, pCT vectors, GOLDILOCKS transposase, CHROMASelect screening, and SMART BIOPROCESSING. Celltheon also sells the OmniCHO Transient Expression Kit as a standalone commercial product for customers performing in-house transient expression.

Product overview

Celltheon offers a portfolio of commercial products and an integrated service platform for complex biologics development and manufacturing. OmniCHO™ is a commercial transient expression kit (the first high-performance CHO-K1 transient kit), while the CELLTHEON SMART™ Expression Platform is a universal preclinical development platform supporting all protein formats. The platform is powered by proprietary technologies including SUPERCELL™ engineered CHO cells, pCT™ Vectors (with CT STABILIZER™ and SIREN Promoter™), GOLDILOCKS TRANSPOSASE™, CHROMASelect™ screening (>100M clones), and SMART BIOPROCESSING™. The company provides end-to-end services spanning developability optimization, transient production, cell line development (5-10g/L titers), upstream/downstream process development, analytical characterization, GLP bioproduction (up to 100g/batch), and tech transfer. Services support multiple protein formats including IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, and single chain homotrimer.

Differentiator

Problem solved

Functional benefit

Brands

  • CELLTHEON SMART™ Expression Platform: A universal platform for all protein formats including IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, and single chain homotrimer.
  • OmniCHO™
  • SUPERCELL™
  • pCT™ Vectors
  • GOLDILOCKS TRANSPOSASE™
  • CHROMASelect™
  • SMART BIOPROCESSING™

Products and services

  • OmniCHO Transient Kit First high-performance CHO-K1 based transient expression kit (vectors, cells, media, transfection agent) for customers performing in-house transient expression workflows, achieving transient titers up to 4.5 g/L with up to 14x improvement over market-leading transient kits for mAbs and >20x improvement for difficult-to-express proteins.
  • CELLTHEON SMART Expression Platform (Custom Contract Services) Universal preclinical development platform supporting all protein formats (IgG, heterodimeric IgG, tandem scFv, bispecific Fc fusion, single chain homotrimer) with integrated cell line development, process development, analytical characterization, GLP bioproduction, and tech transfer services for biopharma clients developing complex biologics.
  • Cell Line Development Service High-titer stable cell line development achieving >8 g/L clones and >3 g/L pools, stable clones stable for >60 generations, with delivery of 4.5 months to RCB or 6 months with full upstream/downstream process development.
  • Upstream Process Development Service Robust upstream process development using stirred-tank bioreactors with 100% reproducibility in ≥200L STR bioreactors, including CQA optimization for charge variants, N-glycan, truncation, and aggregation.
  • Downstream Process Development Service Scalable 3-4 column chromatography process development optimized for high yield and purity, including viral inactivation, filtration, clarification, and formulation via TFF.
  • Developability Optimization Service Assessment and optimization of protein developability properties to improve downstream processing success.
  • Transient Production Service Rapid production, purification, and characterization of hundreds of protein variants with average mAb titers of 2.0 gm/L in 4-5 day culture using CHO and HEK293 cells.
  • Biochemical Analytics Service High-resolution analytical method development including SE-HPLC, LAL endotoxin, titer, ELISA, RP-HPLC, HIC-HPLC, CEX-HPLC, N-Glycan HILIC-HPLC, and kinetics assays.
  • Biological Activity Assay Development Service Cell-based assay development including FACS, cytokine release, cell killing assays, ADCC, CDC, transwell, and custom assays for biological activity characterization.
  • Tox Material Production Service GLP production of high-quality tox study materials with stirred-tank bioreactors up to 100 grams per production batch and low endotoxin (<0.05 EU/mg).
  • Tech Transfer Service Seamless technology transfer of manufacturing processes to CDMOs with GMP-ready BOM, continuous SME support, and 100% successful process reproducibility.

Quantifiable outcome

  • Up to 4.5 g/L transient titers (OmniCHO)
  • +9 more outcomes

Companies that use Celltheon

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Celltheon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Celltheon partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and strategic.

  • Sepragen CorporationcoreTechnology or IntegrationSepragen Corporation provides bio-processing equipment and consumables for protein production and purification. Their technology, covered by 16 patents, is used globally by leading pharma companies. Sepragen's equipment enables Celltheon to expand its biomanufacturing capabilities. Founder/CEO Vinit Saxena serves as Celltheon advisor on chromatography.
  • Keck Graduate InstitutestrategicStrategic or Co-development PartnerAmita Goel is an ABCAB Board Member at Keck Graduate Institute. Dr. Parviz Shamlou previously served as Director of the Amgen Bioprocessing Center at Keck Graduate Institute. Collaborative relationship through board involvement and advisory roles.
  • Contract Development and Manufacturing Organizations (CDMOs)coreChannel Partner/ Reseller/ DistributorCelltheon supports tech transfer to CDMOs for GMP clinical production. Claims 100% process reproducibility in ≥200L STR bioreactors at partner manufacturing sites. Continuous SME support during entire project lifecycle.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Celltheon competitors and assessment

Company assessment

Broad incumbents

  • GenScript ProBio: GenScript ProBio is the CDMO arm of GenScript, offering end-to-end biologics development from cell line construction through GMP manufacturing for mAbs, bsAbs, and recombinant proteins. It is a broader incumbent with similar services but at larger scale and broader geographic reach.
  • AGC Biologics: AGC Biologics is a global CDMO offering mammalian cell line development, process development, and GMP manufacturing for biologics. It competes with Celltheon on cell line and process development but at substantially larger scale across multiple sites.
  • Catalent Biologics: Catalent is a major global CDMO providing cell line development, bioprocess development, and GMP manufacturing for biologics. It is comparable as a broad incumbent serving the same enterprise biopharma customers with overlapping upstream services.
  • Samsung Biologics: Samsung Biologics is a top-tier global CDMO offering cell line development, process development, and large-scale GMP biologics manufacturing services. It competes with Celltheon as a much larger incumbent serving the same biopharma client base.
  • WuXi Biologics: WuXi Biologics is a leading global biologics CDMO with end-to-end capabilities from cell line development through commercial manufacturing. It is a broad incumbent competing for the same biologics development projects as Celltheon across global biopharma.
  • Lonza Biologics: Lonza is one of the world's largest biologics CDMOs, offering comprehensive cell line construction (e.g., GS Xceed), process development, and large-scale GMP manufacturing. It overlaps with Celltheon on cell line development and process development for mAbs and recombinant proteins.

Emerging players

  • AbCellera: AbCellera is a clinical-stage biotech and antibody discovery platform with proprietary technology for identifying and engineering antibodies, including cell line and expression capabilities for difficult-to-express biologics. It is comparable as a technology-driven biologics platform with selective CDMO-like service offerings.

Direct peers

  • ATUM: ATUM (formerly DNA2.0) is a direct peer offering proprietary cell line development and protein expression tools, including its Leap-In Transposase system and CHO/HEK platforms. It competes head-to-head with Celltheon on CHO-based expression technology and synthetic biology services for biologics developers.
  • LakePharma (Curia): LakePharma, now part of Curia, provides contract biologics development and manufacturing services including cell line development, process development, and analytical characterization for mAbs and recombinant proteins. It overlaps directly with Celltheon's end-to-end biologics services offering.
  • KBI Biologics: KBI Biologics is a contract development and manufacturing organization specializing in mammalian cell line development, process development, and cGMP biomanufacturing for mAbs and recombinant proteins. It is a close comparable as a mid-sized biologics CDMO competing for similar biopharma customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Celltheon social profiles

Digital presence

Celltheon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celltheon leadership team

Management profile

Number of profiles

Profiles12 records

Celltheon funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celltheon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltheon

What does Celltheon do?

Celltheon provides custom contract development and manufacturing services for complex biologics, including cell line development, upstream/downstream process development, analytical characterization, GLP bioproduction, and tech transfer. The company leverages a proprietary CHO-K1 based protein expression platform (CELLTHEON SMART Expression Platform) powered by engineered SUPERCELLs, pCT vectors, GOLDILOCKS transposase, CHROMASelect screening, and SMART BIOPROCESSING. Celltheon also sells the OmniCHO Transient Expression Kit as a standalone commercial product for customers performing in-house transient expression.

Is Celltheon a public or private company?

Celltheon is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Celltheon founded?

Celltheon was founded in 2012. It employs 11 to 50 people.

Where is Celltheon based?

Celltheon is headquartered in Union City, United States, in the North America region.

How does Celltheon make money?

Two revenue lines are on record. Custom Contract Services are the primary driver. The others are omniCHO™ Transient Kit Sales.

Who are Celltheon's main competitors?

Broad incumbents on record are GenScript ProBio, AGC Biologics, Catalent Biologics, Samsung Biologics, WuXi Biologics and Lonza Biologics. AbCellera is listed as an emerging player. Direct peers are ATUM, LakePharma (Curia) and KBI Biologics.

Does Celltheon have an API?

No public API is recorded for Celltheon.

What industry is Celltheon in?

Celltheon's product category is Biologics Contract Development & Manufacturing Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireScorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership AgreementScorpius Holdings announced a partnership with Celltheon Corporation to provide cell line development services using Celltheon's GOLDILOCKS platform. The first client signed under the agreement will scale up to GMP manufacturing with Scorpius. The collaboration aims to help clients move from early development to GMP activity.GlobeNewswireScorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership AgreementScorpius Holdings announced a partnership with Celltheon Corporation to provide cell line development services using Celltheon's GOLDILOCKS platform. The first client signed under the agreement will scale up to GMP manufacturing with Scorpius. The collaboration aims to help clients move from early development to GMP activity.Business Wire BlogCelltheon Launches Revolutionary OmniCHO™ Transient Expression KitCelltheon launched its OmniCHO™ Transient Expression Kit, a CHO-K1-based system for preclinical drug development. The kit produces average antibody titers of 2 grams per liter, a 6 to 30-fold cost reduction per milligram of protein, and yields over 1 g/L in 5 days. It is available for immediate purchase.ContractpharmaCytovance, Celltheon Partner to Deliver Complete Platform Solution for mAbs & ProteinsCytovance Biologics and Celltheon partnered to combine Celltheon's CHO-K1 cell line development platform with Cytovance's CDMO services. The collaboration aims to support rising demand for complex biologics in US facilities, offering access to Celltheon's OmniCHO and SMART platforms and Cytovance's cGMP manufacturing with 1000L and 2000L bioreactors.Business Wire BlogCDMO Cytovance Biologics and CDO Celltheon Partner to Offer a Complete, US-based Platform Solution for mAbs and Difficult-to-Express ProteinsCytovance Biologics and Celltheon partnered to offer an integrated platform for monoclonal antibody and difficult-to-express protein production. The arrangement combines Celltheon's CHO-K1 cell line development with Cytovance's cGMP manufacturing, including 1000L and 2000L bioreactors. The collaboration aims to expand customer options for cell line selection and accelerate time to market.PR NewswirePall Corporation and Celltheon Form Strategic Partnership for Biotherapeutics Development and Manufacturing with CELLTHEON SMART™ Expression PlatformPall Corporation formed a strategic partnership with Celltheon Corporation to deliver integrated manufacturing solutions for customers developing biotherapeutics. The partnership aligns Pall Biotech's upstream and downstream processing technologies, including bioreactors and consumables, with Celltheon's SMART™ Expression Platform for mammalian cell-based biologic development. The collaboration aims to provide an end-to-end solution that is cost-effective and time-efficient for research and bioproduction.